Identification of bona fide esophageal adenocarcinoma cell lines.
作者信息
Shoemaker Robert H
出版信息
J Natl Cancer Inst. 2010 Feb 24;102(4):212-3. doi: 10.1093/jnci/djp526. Epub 2010 Jan 14.
PMID:20075369
Abstract
摘要
相似文献
1
Identification of bona fide esophageal adenocarcinoma cell lines.
J Natl Cancer Inst. 2010 Feb 24;102(4):212-3. doi: 10.1093/jnci/djp526. Epub 2010 Jan 14.
2
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
J Natl Cancer Inst. 2010 Feb 24;102(4):271-4. doi: 10.1093/jnci/djp499. Epub 2010 Jan 14.
3
Multi-kinase inhibitors create buzz at ASCO.
Nat Biotechnol. 2005 Jun;23(6):639. doi: 10.1038/nbt0605-639.
4
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
Dis Esophagus. 2008;21(6):514-21. doi: 10.1111/j.1442-2050.2007.00799.x.
5
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
Cancer Treat Rev. 2007 Jun;33(4):381-90. doi: 10.1016/j.ctrv.2007.01.002. Epub 2007 Mar 23.
6
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Gastroenterol Hepatol. 2010 Dec;33(10):741-52. doi: 10.1016/j.gastrohep.2010.05.007. Epub 2010 Sep 18.
7
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Isr Med Assoc J. 2010 Oct;12(10):628-32.
8
Problems with the randomized discontinuation design.
J Clin Oncol. 2006 Oct 1;24(28):4669-70; author reply 4670-1. doi: 10.1200/JCO.2006.08.1026.
9
Sorafenib.
Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5.
10
Sorafenib for HCC: a pragmatic perspective.
Oncology (Williston Park). 2011 Mar;25(3):300, 302.
引用本文的文献
1
Stem Cells, I Presume?
Transfus Med Hemother. 2010 Apr;37(2):56. doi: 10.1159/000299793.
Zotero 插件